JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy.

Détails

ID Serval
serval:BIB_2CF796A49B54
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
JCV-specific cellular immune response correlates with a favorable clinical outcome in HIV-infected individuals with progressive multifocal leukoencephalopathy.
Périodique
Journal of Neurovirology
Auteur⸱e⸱s
Du Pasquier R.A., Clark K.W., Smith P.S., Joseph J.T., Mazullo J.M., De Girolami U., Letvin N.L., Koralnik I.J.
ISSN
1355-0284[print], 1355-0284[linking]
Statut éditorial
Publié
Date de publication
2001
Peer-reviewed
Oui
Volume
7
Numéro
4
Pages
318-322
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, U.S. Gov't, P.H.S.
Publication Status: ppublish
Résumé
Most immunosuppressed individuals who develop progressive multifocal leukoencephalopathy (PML) have a rapid fatal outcome, whereas some become long-term survivors. We explored the impact of the cellular immune response against JC virus (JCV) on the clinical outcome of 7 HIV+ and 3 HIV- individuals with PML. Of the 4 HIV+/PML survivors, all had detectable cytotoxic T lymphocytes (CTL) specific for JCV T or VP 1 proteins compared to none of the 3 HIV+/PML progressors tested. Of the 3 HIV-/PML patients, 1 was recently diagnosed with PML and showed evidence of neurologic improvement without any treatment. This patient had CTL specific for the VP1 protein of JCV. The other 2 HIV-/PML survivors were stable 3-8 years after the diagnosis of PML. They did not have any detectable CTL against JCV. These findings suggest that JCV-specific immune response is associated with favorable outcome in HIV+ individuals with PML. The lack of detectable JCV-specific CTL in 2 HIV-/PML survivors might indicate a burnt-out disease without sufficient antigenic stimulation to maintain the cellular immune response. The detection of JCV-specific CTL in an HIV- patient recently diagnosed with PML, who was showing evidence of neurological improvement without any treatment, indicates that this finding may be used as a favorable prognostic marker of disease evolution in the clinical management of patients with PML. As the quest for an effective treatment of PML continues, JCV-specific cellular immune response deserves further attention because it appears to play a crucial role in the prevention of disease progression.
Mots-clé
AIDS-Related Opportunistic Infections/immunology, AIDS-Related Opportunistic Infections/mortality, Acquired Immunodeficiency Syndrome/immunology, Acquired Immunodeficiency Syndrome/mortality, Humans, Immunity, Cellular/immunology, JC Virus/immunology, Leukoencephalopathy, Progressive Multifocal/immunology, Leukoencephalopathy, Progressive Multifocal/mortality, Prognosis, Survival Rate, T-Lymphocytes, Cytotoxic/immunology, T-Lymphocytes, Cytotoxic/virology
Pubmed
Web of science
Création de la notice
25/01/2008 14:56
Dernière modification de la notice
20/08/2019 13:12
Données d'usage